Name:	Nefiracetam
Development Status:	investigational in U.S.
FDA Phase:	Discontinued
Primary Medical Role:	Potential treatment for Alzheimer's disease.
Role in Alzheimer's Disease:	May improve cognitive function in AD patients by activating central cholinergic transmission.
Pharmacological Role:	Enhances the activity of nicotinic acetylcholine receptors by interacting with a protein kinase C pathway and accelerates acetylcholine turnover and release.
Companies:	Daiichi Sankyo, Inc.

References

Narahashi T, Moriguchi S, Zhao X, Marszalec W, Yeh JZ. Mechanisms of action of cognitive enhancers on neuroreceptors. Biol Pharm Bull. 2004 Nov ;27(11):1701-6. Abstract

Narahashi T, Moriguchi S, Zhao X, Marszalec W, Yeh JZ. Mechanisms of action of cognitive enhancers on neuroreceptors. Biol Pharm Bull. 2004 Nov ;27(11):1701-6. Abstract

Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T. Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J Pharmacol Exp Ther. 2003 Oct 1;307(1):160-7. Abstract

Crespi F. Nefiracetam. Daiichi Seiyaku. Curr Opin Investig Drugs. 2002 May ;3(5):788-93. Abstract

Zhao X, Yeh JZ, Narahashi T. Post-stroke dementia. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors. Ann N Y Acad Sci. 2001 Jun;939:179-86. Abstract

Zhao X, Kuryatov A, Lindstrom JM, Yeh JZ, Narahashi T. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Mol Pharmacol. 2001 Apr;59(4):674-83. Abstract

Nishizaki T, Nomura T, Matuoka T, Kondoh T, Enikolopo G, Sumikawa K, Watabe S, Shiotani T, Yoshii M. The anti- dementia drug nefiracetam facilitates hippocampal synaptic transmission by functionally targeting presynaptic nicotinic ACh receptors. Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62. Abstract

Nishizaki T, Matsuoka T, Nomura T, Kondoh T, Watabe S, Shiotani T, Yoshii M. Presynaptic nicotinic acetylcholine receptors as a functional target of nefiracetam in inducing a long-lasting facilitation of hippocampal neurotransmission. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S82-94. Abstract

Yamada K, Tanaka T, Mamiya T, Shiotani T, Kameyama T, Nabeshima T. Improvement by nefiracetam of beta-amyloid-(1- 42)-induced learning and memory impairments in rats. Br J Pharmacol. 1999 Jan;126(1):235-44. Abstract

Woodruff-Pak DS, Hinchliffe RM. Mecamylamine- or scopolamine-induced learning impairment: ameliorated by nefiracetam. Psychopharmacology (Berl). 1997 May;131 (2):130-9. Abstract

Woodruff-Pak DS, Li YT, Hinchliffe RM, Port RL. Hippocampus in delay eyeblink classical conditioning: essential for nefiracetam amelioration of learning in older rabbits. Brain Res. 1997 Feb 7;747(2):207-18. Abstract

Woodruff-Pak DS, Li YT. Nefiracetam (DM-9384): effect on eyeblink classical conditioning in older rabbits. Psychopharmacology (Berl). 1994 Mar;114(2):200-8. Abstract